Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing

Documenti analoghi

• DPYD and fluoropyrimidines: Using the data as our guide
  di: Christine M. Walko
  Pubblicazione: (2024)
• Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales
  di: Catrin O. Plumpton, et al.
  Pubblicazione: (2026)
• Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study
  di: Côme De Metz, et al.
  Pubblicazione: (2024)
• Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates
  di: Anouk H. E. van Kan, et al.
  Pubblicazione: (2025)
• The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐FU in pancreatic cancer
  di: Hiroyuki Kato, et al.
  Pubblicazione: (2024)